PCIA
BBP icon

Prime Capital Investment Advisors’s Virtus Biotech ETF BBP Stock Holding History

Prime Capital Investment Advisors’s Portfolio BBP Stock Details BBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Sell
11,914
-4,933
-29% -$429K 0.01% 495
2026
Q1 		$1.4M Sell
16,847
-6,880
-29% -$566K 0.02% 427
2025
Q4 		$1.9M Buy
+23,727
New +$1.8M 0.02% 359

Other funds holding BBP

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $403M AUM 42.23% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Prime Capital Investment Advisors's BBP Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its Virtus Biotech ETF (BBP) stake by 29% in Q2 2026, selling an estimated $429K and leaving 11,914 shares worth $1.15M. The position accounts for 0.01% of the portfolio, ranked #495.

Prime Capital Investment Advisors first reported a position in BBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.9M in Q4 2025. 25 funds tracked by Wall St. Rank hold BBP as of Q2 2026.

  • Prime Capital Investment Advisors held 11,914 shares of Virtus Biotech ETF worth $1.15M as of Q2 2026.
  • Prime Capital Investment Advisors sold 4,933 Virtus Biotech ETF shares in Q2 2026, an estimated $429K.
  • Virtus Biotech ETF made up 0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #495 holding.
  • Prime Capital Investment Advisors first reported a position in Virtus Biotech ETF in Q4 2025 and has held it in 3 quarters since.
  • Prime Capital Investment Advisors's Virtus Biotech ETF position peaked at $1.9M in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.